Fintel reports that on August 21, 2023, HC Wainwright & Co. maintained coverage of Kronos Bio (NASDAQ:KRON) with a Buy recommendation.
Analyst Price Forecast Suggests 622.50% Upside
As of August 2, 2023, the average one-year price target for Kronos Bio is 10.40. The forecasts range from a low of 7.07 to a high of $15.75. The average price target represents an increase of 622.50% from its latest reported closing price of 1.44.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Kronos Bio is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -2.43.
What is the Fund Sentiment?
There are 189 funds or institutions reporting positions in Kronos Bio. This is a decrease of 22 owner(s) or 10.43% in the last quarter. Average portfolio weight of all funds dedicated to KRON is 0.07%, an increase of 23.39%. Total shares owned by institutions decreased in the last three months by 4.17% to 34,745K shares. 
The put/call ratio of KRON is 0.00, indicating a bullish outlook.
What are Other Shareholders Doing?
Omega Fund Management holds 3,818K shares representing 6.55% ownership of the company. No change in the last quarter.
Bvf holds 2,813K shares representing 4.82% ownership of the company.
Vida Ventures Advisors holds 2,765K shares representing 4.74% ownership of the company. No change in the last quarter.
Perceptive Advisors holds 1,753K shares representing 3.01% ownership of the company. No change in the last quarter.
Partners Capital Investment Group, Llp holds 1,666K shares representing 2.86% ownership of the company. In it's prior filing, the firm reported owning 528K shares, representing an increase of 68.33%. The firm increased its portfolio allocation in KRON by 85.42% over the last quarter.
Kronos Bio Background Information
(This description is provided by the company.)
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio’s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.
Additional reading:
- Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results Data from the Phase 1 dose escalation portion of the Phase 1/2 KB-0742 study will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets a
- Press Release, dated May 10, 2023.
- Press Release, dated March 15, 2023.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
